Retatrutide, a innovative dual-acting glucose-responsive incretin mimetic, represents a significant progression in peptide treatments for the treatment of type 2 diabetic conditions and, increasingly, weight issues. Unlike many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor activa